Teva Pharmaceutical Industries Ltd (TEVA)
14.05
-0.01
(-0.07%)
USD |
NYSE |
May 07, 11:43
Teva Pharmaceutical Industries Enterprise Value: 32.99B for May 6, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 06, 2024 | 32.99B |
May 03, 2024 | 32.90B |
May 02, 2024 | 33.01B |
May 01, 2024 | 32.90B |
April 30, 2024 | 32.98B |
April 29, 2024 | 33.03B |
April 26, 2024 | 32.71B |
April 25, 2024 | 32.08B |
April 24, 2024 | 31.81B |
April 23, 2024 | 31.81B |
April 22, 2024 | 31.67B |
April 19, 2024 | 31.64B |
April 18, 2024 | 31.55B |
April 17, 2024 | 32.00B |
April 16, 2024 | 31.90B |
April 15, 2024 | 32.06B |
April 12, 2024 | 32.14B |
April 11, 2024 | 32.78B |
April 10, 2024 | 32.75B |
April 09, 2024 | 32.89B |
April 08, 2024 | 33.15B |
April 05, 2024 | 33.20B |
April 04, 2024 | 32.84B |
April 03, 2024 | 33.06B |
April 02, 2024 | 32.77B |
Date | Value |
---|---|
April 01, 2024 | 32.82B |
March 28, 2024 | 33.05B |
March 27, 2024 | 33.40B |
March 26, 2024 | 33.08B |
March 25, 2024 | 32.99B |
March 22, 2024 | 32.80B |
March 21, 2024 | 32.64B |
March 20, 2024 | 32.34B |
March 19, 2024 | 32.19B |
March 18, 2024 | 32.16B |
March 15, 2024 | 32.28B |
March 14, 2024 | 32.36B |
March 13, 2024 | 32.53B |
March 12, 2024 | 32.35B |
March 11, 2024 | 32.19B |
March 08, 2024 | 32.50B |
March 07, 2024 | 32.60B |
March 06, 2024 | 32.40B |
March 05, 2024 | 32.41B |
March 04, 2024 | 32.29B |
March 01, 2024 | 32.36B |
February 29, 2024 | 31.97B |
February 28, 2024 | 31.90B |
February 27, 2024 | 32.14B |
February 26, 2024 | 32.13B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
27.05B
Minimum
Jul 03 2023
43.70B
Maximum
May 07 2019
33.29B
Average
33.18B
Median
Jul 16 2021
Enterprise Value Benchmarks
Viatris Inc | 30.99B |
Alvotech | 4.969B |
AstraZeneca PLC | 260.30B |
Corcept Therapeutics Inc | 2.085B |
GSK PLC | 105.09B |
Enterprise Value Related Metrics
Net Income (Quarterly) | 429.00M |
Revenue (Quarterly) | 4.457B |
Total Expenses (Quarterly) | 3.17B |
EPS Diluted (Quarterly) | 0.41 |
Gross Profit Margin (Quarterly) | 54.18% |
Profit Margin (Quarterly) | 9.63% |
Earnings Yield | -3.35% |
Operating Earnings Yield | 20.24% |
Normalized Earnings Yield | 11.49 |